PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.

Darban SA, Badiee A, Jaafari MR

Nanomedicine (London, England)1 Jun 2017Cited by 21 (Europe PMC)

PMID28565974DOI10.2217/nnm-2017-0069PepBankPUB-28565974

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, PNC-27 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking PNC-27.

01AnimalNot a test of PNC-27 aloneAnimal study (in vivo)Efficacy outcome
In C26 tumors, Doxil bearing 100 PNC27 peptides significantly improved therapeutic efficacy compared with Doxil.
In plain wordsIn mice with C26 tumors, PNC27-Doxil improved treatment efficacy compared with Doxil.
Peptide
PNC-27
Outcome
IncreaseTherapeutic efficacy
Study
mousen: not reported in source
BALB/c mice bearing C26 tumors
Comparator
Doxil
Outcome group
Tumor growth · Cancer
Source sentences
Summary
PNC27-Doxil (100 PNC27 peptide) significantly improved therapeutic efficacy of Doxil without compromising its biodistribution in C26 tumor.
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo studies were performed on BALB/c mice bearing C26 and C57BL/6 mice bearing B16F0 tumor models.
In this study, PNC-27 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking PNC-27.
Report a problemFND-2856597403
02AnimalNot a test of PNC-27 aloneAnimal study (in vivo)Pharmacokinetics
In C26 tumors, Doxil bearing 100 PNC27 peptides did not compromise Doxil biodistribution.
In plain wordsIn mice with C26 tumors, PNC27-Doxil did not compromise biodistribution compared with Doxil.
Peptide
PNC-27
Outcome
No significant changeBiodistribution
Study
mousen: not reported in source
BALB/c mice bearing C26 tumors
Comparator
Doxil
Outcome group
Pharmacokinetics · Cancer
Source sentences
Summary
PNC27-Doxil (100 PNC27 peptide) significantly improved therapeutic efficacy of Doxil without compromising its biodistribution in C26 tumor.
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo studies were performed on BALB/c mice bearing C26 and C57BL/6 mice bearing B16F0 tumor models.
In this study, PNC-27 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking PNC-27.
Report a problemFND-2856597404
03LabNot a test of PNC-27 aloneIn vitro (cells)Activity measurement
In C26 cells, PNC27-Doxil showed significantly greater cellular uptake than Doxil.
In plain wordsIn cells, PNC27-Doxil entered C26 cancer cells more than Doxil.
Peptide
PNC-27
Outcome
IncreaseCellular uptake
Study
n: not reported in source
C26 colon carcinoma cells
Comparator
Doxil
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
PNC27-Doxil showed significant cellular uptake and cytotoxicity in C26 cells compared with Doxil.
1 context sentence(design, population, supporting numbers)
Summary · context
Flow cytometry and confocal analysis were performed on C26 colon carcinoma (HDM2 positive) and B16F0 melanoma (HDM2 negative) cells.
In this study, PNC-27 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking PNC-27.
Report a problemFND-2856597401
04LabNot a test of PNC-27 aloneIn vitro (cells)Efficacy outcome
In C26 cells, PNC27-Doxil showed significantly greater cytotoxicity than Doxil.
In plain wordsIn cells, PNC27-Doxil was more toxic to C26 cancer cells than Doxil.
Peptide
PNC-27
Outcome
IncreaseCytotoxicity
Study
n: not reported in source
C26 colon carcinoma cells
Comparator
Doxil
Outcome group
Tumor growth · Cancer
Source sentences
Summary
PNC27-Doxil showed significant cellular uptake and cytotoxicity in C26 cells compared with Doxil.
1 context sentence(design, population, supporting numbers)
Summary · context
Flow cytometry and confocal analysis were performed on C26 colon carcinoma (HDM2 positive) and B16F0 melanoma (HDM2 negative) cells.
In this study, PNC-27 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking PNC-27.
Report a problemFND-2856597402
05LabNot a test of PNC-27 aloneIn vitro (cells)Activity measurement
In B16F0 cells, the cellular uptake improvement of PNC27-Doxil over Doxil was not observed.
In plain wordsIn cells, PNC27-Doxil did not show the uptake improvement over Doxil in B16F0 cells.
Peptide
PNC-27
Outcome
No significant changeCellular uptake enhancement
Study
n: not reported in source
B16F0 melanoma cells
Comparator
Doxil
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
However, these results were not observed in B16F0 cells.
2 context sentences(design, population, supporting numbers)
Summary · context
PNC27-Doxil showed significant cellular uptake and cytotoxicity in C26 cells compared with Doxil.
Summary · context
Flow cytometry and confocal analysis were performed on C26 colon carcinoma (HDM2 positive) and B16F0 melanoma (HDM2 negative) cells.
In this study, PNC-27 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking PNC-27.
Report a problemFND-2856597405
06LabNot a test of PNC-27 aloneIn vitro (cells)Efficacy outcome
In B16F0 cells, the cytotoxicity improvement of PNC27-Doxil over Doxil was not observed.
In plain wordsIn cells, PNC27-Doxil did not show the toxicity improvement over Doxil in B16F0 cells.
Peptide
PNC-27
Outcome
No significant changeCytotoxicity enhancement
Study
n: not reported in source
B16F0 melanoma cells
Comparator
Doxil
Outcome group
Tumor growth · Cancer
Source sentences
Summary
However, these results were not observed in B16F0 cells.
2 context sentences(design, population, supporting numbers)
Summary · context
PNC27-Doxil showed significant cellular uptake and cytotoxicity in C26 cells compared with Doxil.
Summary · context
Flow cytometry and confocal analysis were performed on C26 colon carcinoma (HDM2 positive) and B16F0 melanoma (HDM2 negative) cells.
In this study, PNC-27 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking PNC-27.
Report a problemFND-2856597406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.